| pubmed-article:7051851 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7051851 | lifeskim:mentions | umls-concept:C0042395 | lld:lifeskim |
| pubmed-article:7051851 | lifeskim:mentions | umls-concept:C1882726 | lld:lifeskim |
| pubmed-article:7051851 | lifeskim:mentions | umls-concept:C0243144 | lld:lifeskim |
| pubmed-article:7051851 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7051851 | pubmed:dateCreated | 1982-10-12 | lld:pubmed |
| pubmed-article:7051851 | pubmed:abstractText | We have investigated the uptake and degradation of vasoactive intestinal peptide (VIP) by rat livers. When liver was perfused with 125I-VIP, less than 20% of the radioactivity was recovered as intact peptide. 125I-VIp bound to specified high-affinity sites on isolated hepatocytes. Half-maximal inhibition of binding occurred at about 1 nM unlabeled VIP. Cell-bound 125I-VIP was degraded to low-molecular-weight products. The percent of 125I-VIP that was bound and degraded was approximately the same at both extremes of the range of VIP concentrations (25-250 pg/ml) reported in portal vein plasma. The lysosomotropic agent chloroquine inhibited 125I-VIP degradation and led to the accumulation of cell-bound 125I-VIP. We conclude that a) most of the VIP secreted from the gastrointestinal tract into portal blood is removed during its passage through the liver, b) VIP binds to specific high-affinity sites on hepatocytes and is probably internalized and degraded by lysosomes, and c) uptake of VIP by liver may serve to prevent the peptide from exerting deleterious systemic effects. | lld:pubmed |
| pubmed-article:7051851 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7051851 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7051851 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7051851 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7051851 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7051851 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7051851 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7051851 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7051851 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7051851 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7051851 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7051851 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7051851 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:7051851 | pubmed:issn | 0002-9513 | lld:pubmed |
| pubmed-article:7051851 | pubmed:author | pubmed-author:McGuiganJ EJE | lld:pubmed |
| pubmed-article:7051851 | pubmed:author | pubmed-author:MisbinR IRI | lld:pubmed |
| pubmed-article:7051851 | pubmed:author | pubmed-author:BuynitzkyS... | lld:pubmed |
| pubmed-article:7051851 | pubmed:author | pubmed-author:MorrisPP | lld:pubmed |
| pubmed-article:7051851 | pubmed:author | pubmed-author:WolfeM MMM | lld:pubmed |
| pubmed-article:7051851 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7051851 | pubmed:volume | 243 | lld:pubmed |
| pubmed-article:7051851 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7051851 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7051851 | pubmed:pagination | G103-11 | lld:pubmed |
| pubmed-article:7051851 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:7051851 | pubmed:meshHeading | pubmed-meshheading:7051851-... | lld:pubmed |
| pubmed-article:7051851 | pubmed:meshHeading | pubmed-meshheading:7051851-... | lld:pubmed |
| pubmed-article:7051851 | pubmed:meshHeading | pubmed-meshheading:7051851-... | lld:pubmed |
| pubmed-article:7051851 | pubmed:meshHeading | pubmed-meshheading:7051851-... | lld:pubmed |
| pubmed-article:7051851 | pubmed:meshHeading | pubmed-meshheading:7051851-... | lld:pubmed |
| pubmed-article:7051851 | pubmed:meshHeading | pubmed-meshheading:7051851-... | lld:pubmed |
| pubmed-article:7051851 | pubmed:meshHeading | pubmed-meshheading:7051851-... | lld:pubmed |
| pubmed-article:7051851 | pubmed:meshHeading | pubmed-meshheading:7051851-... | lld:pubmed |
| pubmed-article:7051851 | pubmed:meshHeading | pubmed-meshheading:7051851-... | lld:pubmed |
| pubmed-article:7051851 | pubmed:meshHeading | pubmed-meshheading:7051851-... | lld:pubmed |
| pubmed-article:7051851 | pubmed:meshHeading | pubmed-meshheading:7051851-... | lld:pubmed |
| pubmed-article:7051851 | pubmed:year | 1982 | lld:pubmed |
| pubmed-article:7051851 | pubmed:articleTitle | Uptake of vasoactive intestinal peptide by rat liver. | lld:pubmed |
| pubmed-article:7051851 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7051851 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7051851 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7051851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7051851 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7051851 | lld:pubmed |
